You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Claims for Patent: 5,972,882

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,972,882

Title:	Treatment of polycystic kidney disease using vasopressin V.sub.2 receptor antagonists
Abstract:	The present invention is directed to the novel treatment of ARPKD and ADPKD by administering a pharmacologically effective amount of a V.sub.2 receptor antagonist. Orally active V.sub.2 receptor antagonists such as OPC-31260, OPC-41061, SR121463A and VPA-985 are administered alone, or in combination to mammalian PKD subjects to reduce the cAMP generated by the increased expression of AVP-V.sub.2 receptor, AQP2 and AQP3, thereby reducing and/or preventing cyst enlargement.
Inventor(s):	Gattone, II; Vincent H. (Overland Park, KS)
Assignee:	University of Kansas Medical Center (Kansas City, KS)
Application Number:	09/211,396
Patent Claims:	1. A method for treating polycystic kidney disease in a mammal comprising administering a therapeutically effective amount of a vasopressin V.sub.2 receptor antagonist to said mammal. 2. The method of claim 1 wherein said vasopressin V.sub.2 receptor antagonist is selected from the group consisting of OPC-31260, OPC-41061, SR121463A, VPA-985 and peptide V.sub.2 antagonists. 3. The method of claim 1 wherein said vasopressin V.sub.2 receptor antagonist is OPC-31260 administered orally to said mammal in a dose of about 60 mg/kg/day. 4. The method of claim 1 wherein said vasopressin V.sub.2 receptor antagonist is SR121463A administered orally to said mammal in a dose of about 2 mg/kg/day. 5. The method of claim 1 wherein said vasopressin V.sub.2 receptor antagonist is VPA-985 administered orally to said mammal in a dose of about 2 mg/kg/day. 6. A method for attenuating azotemia and cyst enlargement in polycystic kidney disease in a mammal comprising administering a therapeutically effective amount of a vasopressin V.sub.2 receptor antagonist selected from the group consisting of OPC-31260, OPC-41061, SR121463A, VPA-9835 and peptide V.sub.2 antagonists. 7. The method of claim 6 wherein said vasopressin V.sub.2 receptor antagonist is OPC-31260 administered orally to said mammal in a dose of about 60 mg/kg/day. 8. The method of claim 6 wherein said vasopressin V.sub.2 receptor antagonist is SR121463A administered orally to said mammal in a dose of about 2 mg/kg/day. 9. The method of claim 6 wherein said vasopressin V.sub.2 receptor antagonist is VPA-985 administered orally to said mammal in a dose of about 2 mg/kg/day.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.